Extracellular vesicles released from cells exposed to reactive oxygen species increase annexin A2 expression and survival of target cells exposed to the same conditions

Ann Kari Grindheim\textsuperscript{a,b} and Anni Vedeler\textsuperscript{a}

\textsuperscript{a}Department of Biomedicine, University of Bergen, Bergen, Norway; \textsuperscript{b}Molecular Imaging Center (MIC), University of Bergen, Bergen, Norway

**ABSTRACT**
Annexin A2 (AnxA2) is present in multiple cellular compartments and interacts with numerous ligands including calcium, proteins, cholesterol, negatively charged phospholipids and RNA. These interactions are tightly regulated by its post-translational modifications. The levels of AnxA2 and its Tyr23 phosphorylated form (pTyr23AnxA2) are increased in many cancers and the protein is involved in malignant cell transformation, metastasis and angiogenesis. Our previous studies of rat pheochromocytoma (PC12) cells showed that reactive oxygen species (ROS) induce rapid, simultaneous and transient dephosphorylation of nuclear AnxA2, most likely associating with PML bodies, while AnxA2 associated with F-actin at the cell cortex undergoes Tyr23 phosphorylation. The pTyr23AnxA2 in the periphery of the cells is incorporated into intraluminal vesicles of multivesicular endosomes and subsequently released to the extracellular space. We show here that extracellular vesicles (EVs) from cells exposed to ROS prime untreated PC12 cells to better tolerate subsequent oxidative stress, thus enhancing their survival. There is an increase in the levels of pTyr23AnxA2 and AnxA2 in the primed cells, suggesting that AnxA2 is involved in their survival. This increase is due to an upregulation of AnxA2 expression both at the transcriptional and translational levels after relatively short term (2 h) exposure to primed EVs.

**Background**
Annexin A2 (AnxA2), a member of a large family of Ca\textsuperscript{2+}-dependent anionic phospholipid-binding proteins, is a key player in tumor progression, neo-angiogenesis and metastasis,\textsuperscript{1-3} i.e. processes that all require cytoskeletal rearrangements and thus result in morphological changes. These changes are related to the ability of AnxA2 to bind certain lipids and both G- and F-actin,\textsuperscript{4} as well as to interact with different cadherin isoforms,\textsuperscript{3,5} are regulated by Tyr23 phosphorylation of AnxA2.\textsuperscript{6} Thus, silencing of AnxA2 expression, inactivation of the Tyr23 site, or treatment with AnxA2 antibodies inhibit cancer metastasis and prolong cell survival.\textsuperscript{7} Up-regulation of AnxA2 and/or its Tyr23 phosphorylation are not only involved in severe malignant development of cancers and a poor prognosis, but may also play a role in chemotherapy resistance.\textsuperscript{8,9} Accordingly, AnxA2 has been associated with DNA replication, transcription and translation\textsuperscript{10} i.e. processes that have been linked to increased resistance of cancer cells to chemotherapy.\textsuperscript{11} The involvement of AnxA2 in the above-mentioned processes points to a protein capable of responding to one or several signaling pathways in different cellular compartments. Our recent results indicate that different subcellular responses may occur simultaneously.\textsuperscript{12} Thus, when cells are exposed to oxidative stress, AnxA2 in the nucleus is dephosphorylated on Tyr23, while cortical AnxA2 is phosphorylated on the same residue by the Src kinase.\textsuperscript{12} AnxA2 itself may in turn act both as a regulator and effector of the Src kinase, at least in the case of v-Src.\textsuperscript{13} Tyr23 phosphorylation of AnxA2 leads to its binding to the cytoplasmic surface of endosomes,\textsuperscript{14} which subsequently develop into multivesicular bodies (MVBs),\textsuperscript{15} due to the invagination of the endosomal membrane. As a consequence of this outside-in conversion in topology,\textsuperscript{16} Tyr23 phosphorylated AnxA2 ends up residing in the lumen of these intraluminal vesicles. As the MVBs fuse with the plasma membrane, these vesicles are released from the MVB lumen to the extracellular space as exosomes.\textsuperscript{16} Thus, the luminal Tyr23...
phosphorylated AnxA2 may be involved in the exosomal transport of cargo between cells. Indeed, it was recently shown that AnxA2 is involved in the packaging of miRNAs into exosomes derived from human breast and prostate cancer cell lines.17 Interestingly, the presence of phosphorylated AnxA2 did not appear to influence the extent of exosomes released from these cells,17 further suggesting a role in cargo transfer. Extracellular vesicles (EVs) are believed to be involved in genetic exchange between cells in the form of transfer of mRNAs and small RNAs,18 thus emerging as important mediators of intercellular communication. For example, it is thought that extracellular vesicle-mediated signaling is involved in the modulation of the tumor microenvironment.19

We recently showed that oxidative stress induced by ROS changes rapidly (within minutes) the subcellular pattern of Tyr23 phosphorylated AnxA2. The nuclear pTyr23AnxA2 is dephosphorylated and while the phosphorylated form partially localizes to nuclear PML bodies, the dephosphorylated form preferentially localizes to SC-35 positive nuclear speckles, possibly involved in transcription. Simultaneously, a pool of cortical AnxA2 becomes Tyr23 phosphorylated by the Src kinase.12 The release of pTyr23AnxA2-containing vesicles to the extracellular space was most pronounced after about 1 h after exposure to ROS, and was significantly reduced after 2 h.12 Since pTyr23AnxA2 has been shown to associate with the endosomal pathway including MVBs, as well as with exosomes released from MVBs,14,15 we investigated whether it would be present in EVs including exosomes released from cells after their exposure to ROS and found this to be the case.12 In fact, AnxA2 has been regarded as a marker of exosomes.20

Figure 1. Two hour pre-incubation of PC12 cells with EVs derived from H2O2-treated cells increases their viability upon subsequent 1 h exposure to H2O2. Exosome-depleted medium was used and EVs were resuspended in 1/20 of the original volume of cell medium. Viability was calculated by trypan blue exclusion assay (n = 6). Viability: p < 0.005.

Figure 2. Pre-incubation of PC12 cells with EVs derived from H2O2-treated cells results in ~2-fold higher levels of pTyr23AnxA2 upon subsequent treatment with H2O2, as compared to cells exposed to H2O2 only. PC12 cells were untreated (A), treated for 15 min with 1 mM H2O2 only (B), or treated for 15 min with 1 mM H2O2 after their pre-incubation for 2 h with EVs released from cells exposed for 1 h to H2O2 (C). pTyr23AnxA2 (green, A–C) was detected using monoclonal antibodies. The DAPI-stained nuclei are shown in blue. Scale bars: 10 μm. The diagrams below each panel show the corresponding intensity profiles along the lines indicated in the respective panels. Panel 2D: Corrected total cell fluorescence (CTCF) was measured from cells (20–30) in the samples shown (panels A–C); CTCF were then divided by the number of cells measured.
Results and discussion

Here, we investigated the functional significance of the release of EVs in response to the exposure of PC12 cells to ROS. EVs including exosomes were isolated from the medium of PC12 cells following their treatment for 1 h with 1 mM H$_2$O$_2$ (peak release of EVs after H$_2$O$_2$ exposure). Untreated PC12 cells were then pre-incubated for 2 h in the presence of these EVs (denoted primed EVs). Indeed, we observed that these cells developed a higher tolerance for a subsequent 1 h exposure to 1 mM H$_2$O$_2$, increasing their viability from ~84% to ~93% (Fig. 1). Similar results regarding viability after exposure to H$_2$O$_2$ have been obtained with MC/9 cells.

Interestingly, the level of pTyr23AnxA2 at the cell cortex increase significantly in cells pre-incubated with primed EVs and subsequently exposed to H$_2$O$_2$ for 15 min when compared to cells only exposed to H$_2$O$_2$ (Fig. 2, compare Panel B with C). It should be noted that not all cells respond to H$_2$O$_2$ treatment by increasing their cortical pool of pTyr23AnxA2. The poorly responding cells apparently contain low initial levels of AnxA2, both in their cytoplasm and nucleus (Fig. 2B and C), most likely due to cell cycle-dependent expression of AnxA2. Therefore, we have only given the mean intensity/cell (Fig. 2D). These analyses are not given for the control cells since the localization of pTyr23AnxA2 is predominantly in the nucleus (Fig. 2A). To verify that the increased levels of pTyr23AnxA2 in cells exposed to primed EVs and subsequently to H$_2$O$_2$ are indeed related to their pre-incubation with primed EVs, a Western blot analysis was performed on lysates from control cells, cells treated with H$_2$O$_2$ alone, cells pre-incubated with primed EVs only, or cells pre-incubated with EVs and subsequently exposed to H$_2$O$_2$ (Fig. 3). It is evident that exposure to ROS in the form of H$_2$O$_2$ leads to increased Tyr23 phosphorylation of AnxA2 in general, while 2 h pre-incubation with EVs from cells previously exposed to primed EVs and subsequently exposed to H$_2$O$_2$ increases the level of total AnxA2 (Fig. 3). Approximately, pre-exposure to EVs from H$_2$O$_2$-treated cells and subsequent H$_2$O$_2$-exposure lead to a higher increase in the level of pTyrAnxA2 than H$_2$O$_2$ treatment alone (Fig. 3, compare lanes 4 and 2). Together with the imaging data (Fig. 2), these results strongly indicate that the pre-exposure of cells to EVs derived from ROS-stressed PC12 cells increase their level of pTyr23AnxA2 during their subsequent ROS-exposure (Figs. 2 and 3).

The increase in the level of total AnxA2 after preincubation with primed EVs (2 h) alone, or combined with exposure to ROS (15 min), could be due to a) cargo delivery of AnxA2 by EVs, or b) increased transcription and/or translation of AnxA2 in these cells. To distinguish between these possibilities, the amount of total cortical AnxA2 was investigated after exposure to ROS alone (Fig. 4B), or in combination with primed EVs (Fig. 4D), and compared to exposure to primed EVs alone (Fig. 4C). While the total cellular level of pTyr23AnxA2 increases after 15 min of oxidative stress without pre-incubation with primed EVs (Fig. 2), there is no equivalent increase in total AnxA2 (Fig. 4G). However, after the priming of cells with EVs for 2 h, there is an almost 2-fold increase in total AnxA2 (Fig. 4G). By contrast, when transcription or translation in the cells incubated with primed EVs was inhibited by Actinomycin D (AcD) and cycloheximide (CHX), respectively, the increase in the level of total AnxA2 was suppressed. This finding suggests that the pre-incubation of PC12 cells with EVs derived from cells exposed to ROS increases the expression of AnxA2, possibly representing an adaptation to oxidative stress.

Furthermore, the data also suggests that AnxA2 is involved in the EV/exosome-mediated response to ROS, in line with results showing the involvement of ROS in metastasis, angiogenesis and tumor growth. ROS is known to modulate the activity of several transcription factors, including hypoxia-inducible factor-1 (HIF-1). Other examples are the transcription factors SP1 and SP3, which are activated...
by ROS, leading to activated GC-boxes in the vascular endothelial growth factor A (VEGF-A) promoter, which in turn leads to increased expression of VEGF-A.27 HIF-1 plays a critical role in inducing chemoresistance and metastasis,28 and may also increase the expression of AnxA2.29 Upregulated expression of AnxA2 is associated with metastasis in

Figure 4. Pre-incubation of PC12 cells with EVs derived from H$_2$O$_2$-treated cells increases the expression of total AnxA2 both at the transcriptional and translational levels. PC12 cells were untreated (A), treated for 15 min with 1 mM H$_2$O$_2$ (B), pre-incubated for 2 h with EVs released from H$_2$O$_2$-treated cells (C–F) either with no additional treatment (C), or with a subsequent 15 min treatment with 1 mM H$_2$O$_2$ (D), in the presence of 3 $\mu$g/ml AcD (E) or 10 $\mu$g/ml CHX (F). Total AnxA2 (green) was detected using monoclonal polyclonal antibodies. The DAPI-stained nuclei are shown in blue. Scale bars: 10 $\mu$m. The diagrams below each panel show the corresponding intensity profiles along the lines indicated in the respective panels. Panel 4G: Corrected total cell fluorescence (CTCF) was measured from cells in the images shown in Panels A–F; CTCF were then divided by the number of cells (20–30) measured.
several cancer types, including gastric adenocarcinoma and colon cancers. It has been observed that the levels of pTyr23AnxA2 and total AnxA2, in particular associated with the plasma membrane, are considerably increased in cells derived from a metastatic tumor, as compared to the primary tumor derived from the same patient. Thus, in addition to its role in intracellular signaling, AnxA2 also appears to be involved in mediating intercellular signaling either directly (for example by binding to small regulatory RNAs in EVs) or indirectly (by being a "responder" in the EV-recipient cell).

Materials and methods

EVs were isolated as previously described. The kit precipitates both EVs that bud off from the plasma membrane and EVs of endosomal origin (termed exosomes) as well as other secreted membrane-enclosed vesicles. Thus, the term EVs will be used. Briefly, EVs were derived from PC12 cells after treatment with H2O2 for 1 h. 1.4 ml ExoQuick-TC was mixed with 7 ml media from PC12 cells exposed to H2O2 for 1 h and grown in exosome-depleted medium (System Biosciences). This was left ON at 4°C for 30 min before a wash of the exosomal pellet in exosome-depleted medium and another centrifugation was performed. The resulting pellet was resuspended in 1 ml exosome-depleted medium before further dilution when added to cells. Fresh PC12 cells were treated with these EVs for 2 h, and subsequently exposed to H2O2 for 15 min or 1 h (viability assays).

Cells, fixed and permeabilised as described earlier, were stained for immunofluorescence with primary antibodies against pTyr23AnxA2 (sc-135753, Santa Cruz Biotechnologies, 1:20) or AnxA2 (ab41803, Abcam, 1:250), with one modification; before staining with the polyclonal antibodies against AnxA2, antigenic sites were exposed by incubation for 5 min with 6 M guanidine-HCl in 50 mM Tris, pH 7.4. This treatment is not necessary to detect pTyrAnxA2. When the fixed cells were treated with guanidine-HCl and stained with polyclonal antibodies against AnxA2 (recognizes aa residues 150–250), AnxA2 was found predominantly associated with the cortical region under the plasma membrane, with an additional faint signal in the rest of the cytoplasm (Fig. 4). However, in non-guanidine-HCl-treated cells the protein was mainly detected in the nucleus (see also ref. 35, in addition to being detected in the cytoplasm (See Fig. 1, Panels I–II in ref. 12).

Fluorescence intensity graphs/profiles were measured in ImageJ 1.48o. Total cellular fluorescence was calculated using ImageJ 1.48o. An outline was drawn around the cells, and integrated density, mean gray value (fluorescence) and area were measured. Background measurements were also carried out. The corrected total cell fluorescence (CTCF) was calculated as: integrated density – (selected area x mean gray value of background). Total cell lysates were prepared from PC12 cells that had been first extensively washed in PBS. Subsequently, the cells were lysed in RIPA buffer (25 mM Tris; pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing 2 mM EGTA. The resultant supernatant after centrifugation at 12000 g for 20 min was the total cell lysate. SDS-PAGE and western blot analysis were performed as described. Total AnxA2 and its Tyr23 phosphorylated form were detected using monoclonal antibodies directed against AnxA2 (610069; BD Biosciences; 1:1000) and pTyr23AnxA2 (sc-135753, Santa Cruz Biotechnologies, 1:200 dilution), respectively. Monoclonal antibodies against tubulin (A01410–40, Genscript, 1:8000) were used as loading control.

Abbreviations

AcD Actinomycin D
AnxA2 Annexin A2
CHX cycloheximide
CTCF corrected total cell fluorescence
EV extracellular vesicle
MVBs multivesicular bodies
PC12 rat pheochromocytoma cell
pTyr23AnxA2 Tyr23 phosphorylated Annexin A2
ROS reactive oxygen species

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

We greatly appreciate Prof. Jaakko Saraste for valuable comments.

Funding

This study was funded by the University of Bergen (A.K.G. and A.V.), Helse Vest (grant no 911499 to A.V.) and The Research Council of Norway (NFR)(grant no 240400/F20 to A.V.).

References

[1] Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008; 216:131–40; PMID:18698663; http://dx.doi.org/10.1002/path.2400
[2] Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, Tsirka SE, Santambrogio L, Hajjar KA. The annexin A2/S100A10 system in health and
A. K. GRINDHEIM AND A. VEDELER

disease: emerging paradigms. J Biomed Biotechnol 2012; 2012:406273; PMID:23193360; http://dx.doi.org/10.1155/2012/406273

Han Y, Ye J, Dong Y, Xu Z, Du Q. Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin. Exp Ther Med 2015; 10:549-54; PMID:26622352

Hayes MJ, Shao D, Bailly M, Moss SE. Regulation of actin dynamics by annexin 2. EMBO J 2006; 25:1816-26; PMID:16601677; http://dx.doi.org/10.1038/sj.emboj.7601078

Hitchcock JK, Katz AA, Schafer G. Dynamic reciprocity: the role of annexin A2 in tissue integrity. J Cell Commun Signal 2014; 8:125-33; PMID:24838661; http://dx.doi.org/10.1007/s12079-014-0231-0

Rescher U, Ludwig C, Konietzko V, Kharitonenkov A, Gerke V. Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion. J Cell Sci 2008; 121:2177-85; PMID:18565825; http://dx.doi.org/10.1242/jcs.028415

Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One 2011; 6:e19390; PMID:21572519; http://dx.doi.org/10.1371/journal.pone.0019390

Chen CY, Lin YS, Chen CL, Chao PZ, Chiou JF, Kuo CC, Lee FP, Lin YF, Sung YH, Lin YT, et al. Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma. Oncotarget 2015; 6:26946-59; PMID:26196246; http://dx.doi.org/10.18632/oncotarget.4521

Vedeler A, Hollas H, Grindheim AK, Radium AM. Multiple roles of annexin A2 in post-transcriptional regulation of gene expression. Curr Protein Pept Sci 2012; 13:401-12; PMID:22708494; http://dx.doi.org/10.2174/138920312801240190

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26; PMID:24060863; http://dx.doi.org/10.1038/nrc3599

Grindheim AK, Hollas H, Radium AM, Saraste J, Vedeler A. Reactive oxygen species exert opposite effects on Tyr23 phosphorylation of the nuclear and cortical pools of annexin A2. J Cell Sci 2016; 129:314-28; PMID:27422826; http://dx.doi.org/10.1242/jcs.173195

Hayes MJ, Moss SE. Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation. J Biol Chem 2009; 284:10202-10; PMID:19193640; http://dx.doi.org/10.1074/jbc.M807043200

Morel E, Gruenberg J. Annexin A2 binding to endosomes and functions in endosomal transport are regulated by tyrosine 23 phosphorylation. J Biol Chem 2009; 284:1604-11; PMID:18990701; http://dx.doi.org/10.1074/jbc.M806499200

Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem 2011; 286:30911-25; PMID:21737841; http://dx.doi.org/10.1074/jbc.M111.271155

Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113 Pt 19:3365-74; PMID:10984428.

Hagiwara K, Katsuda T, Gailhouste L, Kosaka N, Ochiya T. Commitment of Annexin A2 in recruitment of microRNAs into extracellular vesicles. FEBS Lett 2015; 589:4071-8; PMID:26632510; http://dx.doi.org/10.1016/j.febslet.2015.11.036

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654-9; PMID:17486113; http://dx.doi.org/10.1038/nbc1956

Bronsiz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathysyara H, Srinivasan R, Tribolli AJ, Martin CK, Li F, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012; 14:159-67; PMID:NOT_FOUND; http://dx.doi.org/10.1038/nbc12936

Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics 2009; 9:4997-5000; PMID:19810033; http://dx.doi.org/10.1002/pmic.200900351

Eldh M, Ekstrom K, Valadi H, Sjostrand M, Olsson B, Jernas M, Lotvall J. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One 2010; 5:e15353; PMID:2179422; http://dx.doi.org/10.1371/journal.pone.0015353

Chiang Y, Schneiderman MH, Vishwanatha JK. Annexin II expression is regulated during mammalian cell cycle. Cancer Res 1993; 53:6017-21; PMID:8261416

Madureira PA, Hill R, Miller VA, Giacomantonio C, Lee PW, Waisman DM. Annexin A2 is a novel cellular redox regulatory protein involved in tumorigenesis. Oncotarget 2011; 2:1075-93; PMID:22188518; http://dx.doi.org/10.18632/oncotarget.3757

Lee DJ, Kang SW. Reactive oxygen species and tumor metastasis. Mol Cells 2013; 35:93-8; PMID:23456330; http://dx.doi.org/10.1007/s10059-013-0034-9

Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007; 67:10823-30; PMID:18006827; http://dx.doi.org/10.1158/0008-5472.CAN-07-0783

Marinho HS, Real C, Cynne L, Soares H, Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol 2014; 2:535-62; PMID:24634836; http://dx.doi.org/10.1016/j.redox.2014.02.006

Schafer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Hocker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 2003; 278:8190-8; PMID:12509427; http://dx.doi.org/10.1074/jbc.M211999200

Nagaraj GP, Bramhachari PV, Raghu G, El-Rayes BF. Hypoxia inducible factor-1alpha: Its role in colorectal carcinogenesis and metastasis. Cancer Lett 2015; 366:11-8; PMID:26616902; http://dx.doi.org/10.1016/j.canlet.2015.06.005

Huang B, Deora AB, He KL, Chen K, Sui G, Jacovina AT, Almeida D, Hong P, Burgman P, Hajjar KA. Hypoxia-
inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. Blood 2011; 118:2918-29; PMID:21788340; http://dx.doi.org/10.1182/blood-2011-03-341214

[30] Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008; 98:426-33; PMID:18071363; http://dx.doi.org/10.1038/sj.bjc.6604128

[31] Tristante E, Martinez CM, Jimenez S, Mora L, Carballo F, Martinez-Lacaci I, de Torre-Minguela C. Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma. Transl Res 2015; 166:196-206; PMID:25795236; http://dx.doi.org/10.1016/j.trsl.2015.02.006

[32] Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, Gho YS, Kurochkin IV, Mathivanan S, Quesenberry P, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 2014; 3:26913; PMID:25536934

[33] Grindheim AK, Hollas H, Ramirez J, Saraste J, Trave G, Vedeler A. Effect of serine phosphorylation and Ser25 phospho-mimicking mutations on nuclear localisation and ligand interactions of annexin A2. J Mol Biol 2014; 426:2486-99; PMID:24780253; http://dx.doi.org/10.1016/j.jmb.2014.04.019

[34] Peranen J, Rikkonen M, Kaariainen L. A method for exposing hidden antigenic sites in paraformaldehyde-fixed cultured cells, applied to initially unreactive antibodies. J Histochem Cytochem 1993; 41:447-54; PMID:8429208; http://dx.doi.org/10.1177/41.3.8429208

[35] Madureira PA, Hill R, Lee PW, Waisman DM. Genotoxic agents promote the nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage. PLoS One 2012; 7:e50591; PMID:23226323; http://dx.doi.org/10.1371/journal.pone.0050591

[36] McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events. Cell Cycle 2014; 13:1400-12; PMID:24626186; http://dx.doi.org/10.4161/cc.28401